Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Calidi Biotherapeutics Inc. (CLDI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: CLDI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $120
1 Year Target Price $120
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -32.02% | Avg. Invested days 55 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.61M USD | Price to earnings Ratio - | 1Y Target Price 120 |
Price to earnings Ratio - | 1Y Target Price 120 | ||
Volume (30-day avg) 1 | Beta 1.07 | 52 Weeks Range 1.41 - 46.68 | Updated Date 10/17/2025 |
52 Weeks Range 1.41 - 46.68 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.2 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -158.23% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 7076767 | Price to Sales(TTM) 50.83 |
Enterprise Value 7076767 | Price to Sales(TTM) 50.83 | ||
Enterprise Value to Revenue 49.42 | Enterprise Value to EBITDA -1.64 | Shares Outstanding 5349210 | Shares Floating 2505237 |
Shares Outstanding 5349210 | Shares Floating 2505237 | ||
Percent Insiders 20.13 | Percent Institutions 4.19 |
Upturn AI SWOT
Calidi Biotherapeutics Inc.
Company Overview
History and Background
Calidi Biotherapeutics Inc. is a clinical-stage biotechnology company focused on developing oncolytic virotherapies. Founded to leverage the power of oncolytic viruses to stimulate the patientu2019s immune system to fight cancer.
Core Business Areas
- Oncolytic Virotherapy Development: Calidi develops and researches oncolytic virotherapies targeting various cancers. This includes preclinical research, clinical trials, and potential commercialization of these therapies.
Leadership and Structure
David J. Mazzo serves as the CEO. The company has a management team overseeing research, development, and business operations. They have a board of directors to provide guidance.
Top Products and Market Share
Key Offerings
- Vesicular Stomatitis Virus (VSV-CRAd): Calidi's lead product candidate is based on VSV-CRAd. It is currently in clinical trials for various cancer types. Market share data not publicly available. Competitors include companies developing similar oncolytic virus therapies, such as Amgen (T-Vec) and Replimune.
Market Dynamics
Industry Overview
The oncolytic virotherapy market is growing rapidly, driven by the potential to treat cancers with fewer side effects than traditional therapies. Research and development is very competitive.
Positioning
Calidi Biotherapeutics is positioned as a clinical-stage company with a novel oncolytic virus platform. Their competitive advantage lies in their specific VSV-CRAd technology.
Total Addressable Market (TAM)
The global oncolytic virus therapy market is projected to reach billions of dollars. Calidi, in a growing market, hopes to make key clinical progress to compete with established players and grow its market share.
Upturn SWOT Analysis
Strengths
- Novel oncolytic virus platform
- Experienced management team
- Clinical-stage pipeline
- Strong intellectual property
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Relatively small company
- No approved products
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline to new cancer types
- Positive clinical trial results
- Accelerated regulatory approvals
Threats
- Competition from other oncolytic virus therapies
- Clinical trial failures
- Regulatory hurdles
- Financing challenges
Competitors and Market Share
Key Competitors
- AMGN
- RPIM
- MRTX
Competitive Landscape
Calidi faces stiff competition from larger, more established pharmaceutical companies. However, their novel VSV-CRAd platform has the potential to differentiate them from competitors.
Growth Trajectory and Initiatives
Historical Growth: Data not available due to company's early stage.
Future Projections: Future growth depends heavily on the success of their clinical trials and ability to secure funding or partnerships.
Recent Initiatives: Focus on advancing their clinical trials and expanding their VSV-CRAd platform to new indications.
Summary
Calidi Biotherapeutics is a promising clinical-stage company developing oncolytic virotherapies. While it faces significant financial and regulatory challenges, the company's innovative VSV-CRAd platform and experienced leadership team position it for potential growth. Its success hinges on positive clinical trial outcomes, successful fund raising, and strategic partnerships. It must be mindful of competitors in a crowded space.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual research and consultation with a qualified financial advisor. Market share data is estimated based on available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Calidi Biotherapeutics Inc.
Exchange NYSE MKT | Headquaters San Diego, CA, United States | ||
IPO Launch date 2021-11-01 | CEO & Director Dr. Eric E. Poma Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 28 | Website https://www.calidibio.com |
Full time employees 28 | Website https://www.calidibio.com | ||
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, develops allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses in the United States. Its product pipeline comprises CLD-101, which is in Phase 1b/2 clinical trial for the treatment of high-grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck squamous cell carcinoma, and soft tissue sarcoma, which is in pre-clinical studies; CLD-301 for multiple indications, which is in preclinical studies; and CLD-400 for certain lung cancer and metastatic solid tumors. The company also offers oncolytic virus platforms, such as NeuroNova, SuperNova, and RTNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.